1. one thing no one is talking about is enrollment. if company is thinking on adding, it could be sub types. plus, why would you look to enlarge the trial if you have enrolment issues? LOL Enrolment is well underway.
2. Someone was concerned over cash in hand, did you forget that Germany is going to pay NWBO? even 25% poulation of 12000 GBM annual patient treatment by NWBO at mere $37,000 is whopping $111 million/year.
3. Linda talked about survival, I am sure it was OS and not PFS. note that primary end point is PFS and not OS which is secondary. Heck its been 14 weeks since 61 events hit on Dec 10th to today, that is almost twice the SOC PFS rate and we are yet to hit 81 events. With 75% is in DCVax and 25% in SOC, given slow enrolment, it may be hard to get to that 81 events IMHO, meaning PFS in DCVax must be superior.
4. I am very positive here with the fact ASCO coming up.
I bought a boat load more today. Not worried at all.
News 
Market Data 
Discover 
AI
